Your browser doesn't support javascript.
loading
Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer / 中华外科杂志
Zhonghua Wai Ke Za Zhi ; (12): 546-549, 2023.
Article en Zh | WPRIM | ID: wpr-985806
Biblioteca responsable: WPRO
ABSTRACT
Pancreatic cancer is a highly malignant tumor. About 75% of patients with pancreatic cancer who underwent radical surgical resection will still experience postoperative recurrence. Neoadjuvant therapy could improve outcomes in patients with borderline resectable pancreatic cancer,has become a consensus;however it is still controversial in resectable pancreatic cancer. Limited high-quality randomized controlled trial studies support the routine initiation of neoadjuvant therapy in resectable pancreatic cancer. With the development of new technologies, such as next-generation sequencing, liquid biopsy, imaging omics, and organoids, patients are expected to benefit from the precision screening of potential candidates for neoadjuvant therapy and individualized treatment strategy.
Asunto(s)
Texto completo: 1 Base de datos: WPRIM Asunto principal: Neoplasias Pancreáticas / Terapia Neoadyuvante Límite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Año: 2023 Tipo del documento: Article
Texto completo: 1 Base de datos: WPRIM Asunto principal: Neoplasias Pancreáticas / Terapia Neoadyuvante Límite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Año: 2023 Tipo del documento: Article